Continued circulation of mpox: an epidemiological and phylogenetic assessment, European Region, 2023 to 2024.

Humans Europe / epidemiology Phylogeny Disease Outbreaks Male Female Adult Middle Aged Adolescent Young Adult Child Aged Population Surveillance Child, Preschool Incidence
Europe MPXV Mpox WHO European Region orthopoxvirus outbreak

Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
Jul 2024
Historique:
medline: 5 7 2024
pubmed: 5 7 2024
entrez: 5 7 2024
Statut: ppublish

Résumé

During the summer of 2023, the European Region experienced a limited resurgence of mpox cases following the substantial outbreak in 2022. This increase was characterised by asynchronous and bimodal increases, with countries experiencing peaks at different times. The demographic profile of cases during the resurgence was largely consistent with those reported previously. All available sequences from the European Region belonged to clade IIb. Sustained efforts are crucial to control and eventually eliminate mpox in the European Region.

Identifiants

DOI: 10.2807/1560-7917.ES.2024.29.27.2400330 PMID: 38967012
pubmed: 38967012
doi: 10.2807/1560-7917.ES.2024.29.27.2400330
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Aisling M Vaughan (AM)

These authors contributed equally as first authors.
World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.

Mohammed Afzal (M)

These authors contributed equally as first authors.
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Priyanka Nannapaneni (P)

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Mathias Leroy (M)

World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.

Xanthi Andrianou (X)

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Jeffrey Pires (J)

World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.

Silvia Funke (S)

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Celine Roman (C)

World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.

Juliana Reyes-Uruena (J)

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Stephan Aberle (S)

Medical University of Vienna, Centre for Virology, Vienna, Austria.

Aristos Aristodimou (A)

Medical and Public Health Services, Nicosia, Cyprus.

Gudrun Aspelund (G)

Centre for Health Security and Communicable Disease Control, Directorate of Health, Reykjavik, Iceland.

Kirsty F Bennet (KF)

United Kingdom Health Security Agency, London, United Kingdom.

Antra Bormane (A)

Center for Disease Prevention and Control of Latvia, Department of Infectious Diseases Risk Analysis and Prevention, Riga, Latvia.

Anna Caraglia (A)

Ministry of Health, Rome, Italy.

Hannah Charles (H)

United Kingdom Health Security Agency, London, United Kingdom.

Emilie Chazelle (E)

Santé publique France, the French National Public Health Agency, Saint-Maurice, France.

Iva Christova (I)

National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.

Orna Cohen (O)

Division of Epidemiology, Ministry of Health, Jerusalem, Israel.

Costas Constantinou (C)

Medical and Public Health Services, Nicosia, Cyprus.

Simon Couvreur (S)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Asuncion Diaz (A)

National Centre of Epidemiology, CIBER in Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.

Kateřina Fabiánová (K)

National Institute of Public Health, Centre for Epidemiology and Microbiology, Department of Infectious Disease Epidemiology, Prague, Czechia.

Federica Ferraro (F)

Ministry of Health, Rome, Italy.

Marte Petrikke Grenersen (MP)

Norwegian Institute of Public Health (NIPH), Oslo, Norway.

Eva Grilc (E)

NIJZ (NIPH), Centre for Communicable Diseases, Ljubljana, Slovenia.

Tuula Hannila-Handelberg (T)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Anne Kathrine Hvass (AK)

Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.

Derval Igoe (D)

HSE Public Health: National Health Protection Office, Dublin, Ireland.

Klaus Jansen (K)

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.

Denisa Janță (D)

National Institute of Public Health, Bucharest, Romania.

Styliani Kaoustou (S)

Directorate of Epidemiological Surveillance and Intervention for Communicable Diseases, National Public Health Organization, Marousi, Greece.

Anders Koch (A)

Department of Infectious Diseases, Rigshospitalet University Hospital, Copenhagen, Denmark.
Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.

Mirjana Lana Kosanovic Licina (ML)

Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia.

Stefka Krumova (S)

National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.

Anton Labutin (A)

Swiss Federal Office of Public Health, Bern, Switzerland.

Raskit Lachmann (R)

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.

Amaryl Lecompte (A)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Rémi Lefrançois (R)

Santé publique France, the French National Public Health Agency, Saint-Denis, France.

Viktorija Leitena (V)

Center for Disease Prevention and Control of Latvia, Department of Infectious Diseases Risk Analysis and Prevention, Riga, Latvia.

Kirsi Liitsola (K)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Ivan Mlinarić (I)

Croatian Institute of Public Health, Division for Epidemiology of Communicable Diseases, Zagreb, Croatia.

Zohar Mor (Z)

School of Health Sciences, Ashkelon Academic College, Ashkelon, Israel.
Division of Epidemiology, Ministry of Health, Jerusalem, Israel.

Martha Neary (M)

HSE Health Protection Surveillance Centre, Dublin, Ireland.

Alina Novacek (A)

Austrian Agency for Health and Food Safety, Vienna, Austria.

Magnus Wenstøp Øgle (MW)

Norwegian Institute of Public Health (NIPH), Oslo, Norway.

Hana Orlíková (H)

Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czechia.
National Institute of Public Health, Centre for Epidemiology and Microbiology, Department of Infectious Disease Epidemiology, Prague, Czechia.

Kalliopi Papadima (K)

Directorate of Epidemiological Surveillance and Intervention for Communicable Diseases, National Public Health Organization, Marousi, Greece.

Moa Rehn (M)

Public Health Agency of Sweden (PHAS), Solna, Sweden.

Malgorzata Sadkowska-Todys (M)

National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.

Anca Sîrbu (A)

National Institute of Public Health, Bucharest, Romania.

Klara Sondén (K)

Public Health Agency of Sweden (PHAS), Solna, Sweden.

Berta Suárez (B)

Coordinating Centre for Health Alerts and Emergencies (CCAES), Directorate General of Public Health, Ministry of Health, Madrid, Spain.

Marianna Thordardottir (M)

Centre for Health Security and Communicable Disease Control, Directorate of Health, Reykjavik, Iceland.

Paula Vasconcelos (P)

Public Health Emergency Centre, Directorate-General of Health (DGS), Lisbon, Portugal.

Joao Vieira Martins (J)

Directorate of Information and Analysis, Directorate-General of Health, Lisbon, Portugal.

Karolina Zakrzewska (K)

National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.

Marc-Alain Widdowson (MA)

These authors contributed equally as last authors.
World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.

Céline M Gossner (CM)

These authors contributed equally as last authors.
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Continued circulation of mpox: an...
questionsmedicales.fr › Régions géographiques › Europe › Continued circulation of mpox: an...
questionsmedicales.fr › Sciences de l'information › Phylogenèse › Continued circulation of mpox: an...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Continued circulation of mpox: an...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Surveillance de la population › Continued circulation of mpox: an...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › Continued circulation of mpox: an...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Continued circulation of mpox: an...